力诺药包9月25日获融资买入564.17万元，融资余额1.76亿元

Core Viewpoint - Linuo Pharmaceutical Packaging Co., Ltd. has experienced a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its business performance [2] Financing Summary - On September 25, Linuo Pharmaceutical's stock price fell by 0.29%, with a trading volume of 50.45 million yuan [1] - The financing buy-in amount for Linuo Pharmaceutical on the same day was 5.64 million yuan, while the financing repayment was 6.91 million yuan, resulting in a net financing outflow of 1.27 million yuan [1] - As of September 25, the total financing and securities lending balance for Linuo Pharmaceutical was 176 million yuan, which accounts for 4.29% of its market capitalization [1] - The current financing balance is above the 80th percentile level over the past year, indicating a high level of financing activity [1] Business Performance Summary - As of June 30, 2025, Linuo Pharmaceutical reported a revenue of 499 million yuan, a year-on-year decrease of 11.07% [2] - The net profit attributable to shareholders for the same period was 40.97 million yuan, reflecting a year-on-year decline of 20.12% [2] - The company has distributed a total of 139 million yuan in dividends since its A-share listing, with 92.18 million yuan distributed over the past three years [2] Shareholder and Institutional Holdings Summary - The number of shareholders for Linuo Pharmaceutical reached 11,100 as of June 30, 2025, an increase of 17.08% compared to the previous period [2] - The average number of circulating shares per shareholder decreased by 12.16% to 21,522 shares [2] - Among the top ten circulating shareholders, notable changes include a reduction in holdings by Guotai Junan's funds, with the sixth-largest shareholder decreasing by 1.55 million shares [2]